Company / Capital Returned to Shareholders
Integra Lifesciences Holdings Capital Returned to Shareholders History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Returned to Shareholders
$221.0K
FY2025
5-year range
$0 / $275.0M
FY2021-FY2025
Trend
-99.6%
vs FY2024
Sector context
#94 of 108
Health Care
What the data says
Integra Lifesciences Holdings's capital returned to shareholders of $221,000 is lower than 87% of companies in the Health Care sector (FY2025). Capital Returned to Shareholders has fluctuated over the past 8 years, ranging from $0 in FY2021 to $275M in FY2023.
Based on SEC 10-K filings.
$221,000 in FY2025 with a 5-year CAGR of -70.6%.
Declined from $275M to $221,000 over the past 2 years.
Health Care sector context is included.
Capital Returned to Shareholders over time
Growth rates
- 3-Year CAGR
- -87.9%
- 5-Year CAGR
- -70.6%
- 10-Year CAGR
- -
Sector benchmark
-100.0% below sector average
Key checks
Key Insights
- 5-year CAGR of -70.6%, indicating a declining trend.
- In FY2025, capital returned to shareholders decreased 99.6% year-over-year.
- Ranks #94 out of 108 companies in the Health Care sector.
- Peak capital returned to shareholders was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 0.44 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital Returned to ShareholdersValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $221.0K | -99.6% |
| FY2024 | $52.5M | -80.9% |
| FY2023 | $275.0M | +120.0% |
| FY2022 | $125.0M | - |
| FY2021 | $0 | -100.0% |
| FY2020 | $100.0M | - |
| FY2019 | $0 | - |
| FY2018 | $0 | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026